

CPT® Editorial Summary of Panel Actions October 2021 Electronic Meeting

CPT® Editorial Summary of Panel Actions October 2021

Please be aware that this action is a reflection of the discussion at the most recent telephonic Panel meeting.

The following approved code, 0004A, is effective from September 22, 2021.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the AMA Website.

Name	Code #	Description of Editorial Panel Action	Effective Date
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines	# ₩•91307	Accepted addition of code 91307 to report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines; accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include code 91307; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration
Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only	●0071A ●0072A	Accepted addition of codes 0071A, 0072A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91307); accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include codes 0071A, 0072A; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration